Barriers And Interventions - NAPLEX

1. A patient values work alertness more than tight glucose control. Which action is most person-centered?
   Answer: Time doses around work hours Person-centered care means tailoring the plan to what the patient values most. Since work alertness is the priority, adjusting dose timing around work hours protects their functioning while still managing diabetes. The tempting wrong answer is pushing tight glucose control, which puts the clinician's goal ahead of the patient's stated preference.
2. A 34-year-old woman (weight 59 kg) with iron deficiency anemia is prescribed ferrous sulfate 325 mg (65 mg elemental iron) once daily. She reports she stopped it because it caused constipation and she did not know she could do anything about it. Labs: hemoglobin 9.8 g/dL, ferritin 8 ng/mL, serum creatinine 0.8 mg/dL. Social history: limited health literacy; finances limited but stable. Allergies: none. What is the most appropriate intervention for this adherence barrier?
   Answer: Counsel on strategies to improve tolerability (e.g., lower dose or every-other-day dosing if appropriate, hydration/fiber, stool softener if needed) and clarify expected duration and monitoring Overcoming barriers to effective medication therapy involves addressing side effects like constipation to sustain iron supplementation. The key patient-specific barrier is constipation from ferrous sulfate, causing discontinuation due to lack of management knowledge. Counseling on tolerability strategies is the best choice as it provides practical solutions, clarifies duration, and improves adherence. Stopping for a multivitamin lacks sufficient iron, while taking with calcium reduces absorption. IV iron bypasses prescriber. A transferable pearl is to proactively counsel on GI mitigation for oral iron. In practice, employ a framework of identifying side effects, offering evidence-based remedies, and following up.
3. A 54-year-old man (weight 96 kg) with hypertension and chronic back pain takes amlodipine 5 mg daily (adherent) and was prescribed duloxetine 30 mg daily for neuropathic pain but stopped after 2 days due to nausea. Labs: serum creatinine 1.0 mg/dL, alanine aminotransferase 32 units/L. Social history: works nights, limited time for follow-up; good insurance. Allergies: none. What is the most appropriate intervention for this adherence barrier?
   Answer: Recommend restarting duloxetine 30 mg daily with food and counseling that nausea may improve after 1–2 weeks, and schedule a follow-up call to reassess tolerability Overcoming barriers to effective medication therapy entails managing transient side effects to prevent premature discontinuation. The key patient-specific barrier is nausea from duloxetine, leading to stopping after minimal use despite pain needs. Recommending restart with food and follow-up is the best choice as it mitigates nausea, educates on adaptation, and monitors progress. Stopping permanently and using high-dose ibuprofen risks GI/renal issues, while doubling the dose may worsen side effects. Adding ondansetron indefinitely adds unnecessary therapy. A transferable pearl is to anticipate and counsel on common SNRI side effects like nausea resolving over time. In practice, employ a framework of assessing side effect timing, offering mitigation strategies, and planning follow-ups.
4. A 39-year-old man (weight 82 kg) with newly diagnosed hypertension is prescribed lisinopril 10 mg daily. He returns stating he stopped it after 3 days because he thought "once daily" meant once when he feels stressed, and he is worried about taking it long-term. Vitals today: blood pressure 156/94 mmHg. Labs: serum creatinine 0.9 mg/dL, potassium 4.2 mEq/L. Social history: limited health literacy and no primary care follow-up scheduled; has insurance. Allergies: none. Which strategy best addresses this patient's health literacy issue?
   Answer: Use plain language to explain daily preventive use, provide a simple written schedule, and confirm understanding using teach-back Overcoming barriers to effective medication therapy necessitates clear communication to correct misunderstandings in patients with limited health literacy. The key patient-specific barrier is misinterpretation of dosing instructions due to low health literacy, leading to early discontinuation and uncontrolled hypertension. Using plain language with a written schedule and teach-back is the best choice as it simplifies concepts, ensures comprehension, and promotes long-term adherence. Explaining detailed pharmacology overwhelms rather than clarifies, while advising symptomatic use promotes non-adherence and risks complications. Increasing the dose compensates poorly without addressing understanding. A transferable pearl is to employ teach-back to verify patient grasp of asymptomatic disease management. In practice, adopt a framework of assessing literacy, using simple tools, and scheduling follow-ups for reinforcement.
5. A 45-year-old woman (weight 78 kg) with asthma and allergic rhinitis presents for inhaler refill. Current medications: fluticasone/salmeterol 250/50 mcg 1 inhalation twice daily (uses only when symptomatic), albuterol metered-dose inhaler 2 puffs every 4–6 hours as needed (uses daily), cetirizine 10 mg daily. No recent labs needed; serum creatinine 0.8 mg/dL from last month. She speaks primarily Spanish and nods during counseling but later admits she is not sure which inhaler is "daily" versus "rescue." Social history: limited English proficiency; relies on her teenage son to translate; works two jobs. Allergies: none. How should the pharmacist address the patient's cultural or language barrier?
   Answer: Use a qualified medical interpreter and provide Spanish written instructions with inhaler technique demonstration and teach-back Overcoming barriers to effective medication therapy includes addressing language and cultural differences to ensure proper understanding and use of medications. The key patient-specific barrier is limited English proficiency, resulting in confusion between maintenance and rescue inhalers despite nodding during counseling, compounded by reliance on her son for translation. Using a qualified medical interpreter with Spanish instructions and teach-back is the best choice as it ensures accurate communication, demonstrates proper technique, and respects cultural needs without family burden. Providing counseling only in English is suboptimal as it ignores the language barrier and risks misunderstanding, while asking the son to translate is inappropriate due to potential inaccuracies and privacy concerns. Switching to nebulized albuterol fails to address the root communication issue and may increase complexity with her busy schedule. A clinical pearl is to always employ professional interpreters for non-English speakers to avoid errors in medication education. In practice, use a framework of identifying language needs, integrating cultural competence, and confirming adherence through demonstration.
6. A bilingual spouse interprets and downplays adverse effects. Which action best safeguards patient-centered assessment?
   Answer: Use a professional interpreter A professional interpreter ensures complete, unbiased communication, so adverse effects aren't minimized and your assessment reflects the patient's true status. Translated handouts are tempting but don't address the spouse's filtering during the live conversation. Use a neutral interpreter rather than relying on family members or simplified English.
7. A 67-year-old woman (70 kg) with atrial fibrillation and prior ischemic stroke is taking apixaban 5 mg twice daily but reports she has been taking it once daily for the past month because the copay increased to $180/month. Current medications: apixaban 5 mg twice daily (nonadherent due to cost), metoprolol succinate 50 mg daily (adherent), hydrochlorothiazide 25 mg daily (adherent). Labs: serum creatinine 1.0 mg/dL, aspartate aminotransferase 18 U/L, alanine aminotransferase 20 U/L; no known drug allergies; blood pressure 132/78 mmHg. She has stable housing but limited income and does not qualify for Medicaid; transportation is reliable. What is the optimal alternative therapy given the patient's financial situation?
   Answer: Switch to warfarin with INR monitoring and provide counseling on consistent vitamin K intake and follow-up monitoring plan Overcoming barriers to effective medication therapy requires identifying cost-effective alternatives that maintain therapeutic efficacy while addressing financial constraints. This patient's barrier is the high cost of apixaban ($180/month), leading to dangerous underdosing of a critical anticoagulant in a high-risk patient with prior stroke. Switching to warfarin with INR monitoring (Option A) is the BEST intervention because it provides effective anticoagulation at minimal cost (generic warfarin ~$4-10/month) while maintaining stroke prevention efficacy, though requiring monitoring. Option B (continuing reduced apixaban) is dangerous as underdosing provides inadequate stroke protection without reducing bleeding risk. Option C (rivaroxaban) incorrectly assumes once-daily dosing is cheaper—rivaroxaban is similarly expensive to apixaban and still unaffordable. Option D (aspirin alone) is grossly inadequate for stroke prevention in atrial fibrillation with prior stroke, offering only 20% risk reduction versus 70% with anticoagulation. The clinical pearl is that when cost barriers prevent adherence to novel oral anticoagulants, warfarin remains a highly effective, affordable alternative despite monitoring requirements, especially for high-risk patients.
8. A 63-year-old man (weight 90 kg) with hypertension and benign prostatic hyperplasia lives in a rural area. Current medications: amlodipine 10 mg daily (adherent), tamsulosin 0.4 mg nightly (misses refills), and hydrochlorothiazide 25 mg daily (misses refills). Labs: serum creatinine 1.1 mg/dL, potassium 3.9 mEq/L. He reports his pharmacy is 35 miles away and he cannot drive due to vision problems; he runs out of medications for 1–2 weeks at a time. Social history: fixed income, limited transportation; has a phone. Allergies: none. What is the most appropriate intervention for this adherence barrier?
   Answer: Arrange synchronized refills with 90-day supplies and enroll the patient in mail delivery or courier service, with reminder calls/texts Overcoming barriers to effective medication therapy requires addressing logistical issues like transportation to ensure consistent access to medications. The key patient-specific barrier is limited transportation in a rural area, causing frequent medication shortages and non-adherence to tamsulosin and hydrochlorothiazide. Arranging synchronized 90-day refills with mail delivery and reminders is the best choice as it minimizes trips, ensures supply continuity, and uses available phone access for support. Recommending a home BP cuff and stopping medications risks uncontrolled hypertension without monitoring, while advising to double doses is unsafe and promotes improper use. Asking a neighbor without consent violates privacy and doesn't solve ongoing access. A transferable pearl is to leverage mail-order pharmacies for patients with transportation barriers. In practice, apply a framework of assessing access issues, synchronizing refills, and integrating technology like reminders for sustained adherence.
9. A 56-year-old woman (weight 83 kg) with hypertension and migraines is prescribed propranolol 40 mg twice daily but often misses the midday dose due to her job. Current medications: propranolol 40 mg twice daily (misses 4–5 doses/week), sumatriptan 50 mg as needed, hydrochlorothiazide 25 mg daily (adherent). Labs: serum creatinine 0.9 mg/dL, potassium 4.0 mEq/L. Social history: works long shifts, wants fewer daily doses; finances stable. Allergies: none. Which action should the pharmacist take to simplify this patient's regimen?
   Answer: Coordinate with the prescriber to consider switching to an appropriate once-daily extended-release beta-blocker formulation and set refill reminders Overcoming barriers to effective medication therapy requires simplifying regimens and addressing lifestyle factors to improve adherence and therapeutic success. Here, the primary barrier is the patient's work schedule causing frequent missed midday doses of propranolol, compounded by her preference for fewer daily administrations. Coordinating with the prescriber to switch to a once-daily extended-release beta-blocker while setting refill reminders is the best choice, as it reduces dosing frequency, aligns with her needs, and maintains effective hypertension and migraine management. Taking both doses together is incorrect due to risks of excessive peak effects and reduced efficacy; adding another medication increases complexity without simplifying the regimen; stopping propranolol for daily sumatriptan is suboptimal, as sumatriptan is not indicated for daily prevention and could cause medication overuse headache. A key clinical pearl is that regimen simplification, such as using extended-release formulations, often improves adherence in busy patients. For similar cases, employ a framework of assessing lifestyle barriers, prioritizing once-daily options, and incorporating reminders to sustain long-term compliance.
10. A 70-year-old man (weight 68 kg) with deep vein thrombosis is taking apixaban 5 mg twice daily but admits he often skips doses because he believes anticoagulants are "only needed when the leg hurts." Current medications: apixaban 5 mg twice daily (misses several doses weekly), acetaminophen 500 mg as needed. Labs: serum creatinine 1.0 mg/dL, alanine aminotransferase 20 units/L. Social history: adequate finances and transportation; low health literacy. Allergies: none. Which strategy best addresses this patient's health literacy issue?
    Answer: Provide a simplified explanation of clot prevention, use teach-back, and set up daily reminders (phone alarm) for twice-daily dosing Overcoming barriers to effective medication therapy includes educating patients on medication purposes to dispel myths and improve adherence. The key patient-specific barrier is misunderstanding anticoagulants' role, leading to skipped apixaban doses based on symptoms and increased thrombosis risk. Providing simplified explanations with teach-back and reminders is the best choice as it corrects misconceptions, reinforces twice-daily importance, and fits his literacy level. Switching to warfarin adds monitoring burden without addressing literacy, while taking both doses once daily alters pharmacokinetics and efficacy. Brief counseling without tools fails to engage effectively. A clinical pearl is to link medication use to tangible benefits like preventing clots in low-literacy education. In practice, use a framework of identifying misconceptions, simplifying messages, and incorporating reminders for regimen adherence.
11. A 76-year-old woman (weight 55 kg) with heart failure with reduced ejection fraction, hypertension, and type 2 diabetes mellitus brings a bag of medications and says she is "overwhelmed." Current medications: carvedilol 12.5 mg twice daily (often forgets morning dose), lisinopril 10 mg daily, furosemide 20 mg twice daily (sometimes takes both tablets at bedtime), spironolactone 25 mg daily, metformin 500 mg twice daily, and acetaminophen 650 mg three times daily as needed. Labs: serum creatinine 1.2 mg/dL, potassium 4.6 mEq/L, hemoglobin A1c 7.1%. Social history: mild cognitive impairment, limited caregiver support, adequate finances. Allergies: none. Which action should the pharmacist take to simplify this patient's regimen?
    Answer: Coordinate with the prescriber to switch carvedilol to an evidence-based once-daily beta-blocker option if appropriate, and provide a pill organizer with a clear dosing schedule Overcoming barriers to effective medication therapy entails simplifying regimens for patients overwhelmed by complexity to improve adherence and outcomes. The key patient-specific barrier is regimen complexity with multiple daily doses, exacerbated by mild cognitive impairment and forgotten doses, leading to suboptimal heart failure management. Coordinating a switch to a once-daily beta-blocker with a pill organizer is the best choice as it reduces dosing frequency, aligns with evidence-based options, and provides organizational support. Recommending furosemide at bedtime is suboptimal as it may cause nocturia, disrupting sleep, while suggesting to stop carvedilol ignores its therapeutic necessity. Adding another diuretic increases complexity without simplifying the regimen. A clinical pearl is to prioritize once-daily formulations when possible to enhance adherence in cognitively impaired patients. In practice, use a framework of evaluating pill burden, consulting prescribers for simplifications, and incorporating adherence aids like organizers.
12. A 70-year-old woman (68 kg) with a history of deep vein thrombosis is taking warfarin with a target international normalized ratio (INR) of 2–3 but has missed two INR appointments this month because she cannot drive and the anticoagulation clinic is 25 miles away. Current medications: warfarin 5 mg daily (variable adherence to monitoring), amlodipine 5 mg daily (adherent), sertraline 50 mg daily (adherent). Labs: last INR 3.8 two weeks ago; serum creatinine 0.8 mg/dL, alanine aminotransferase 20 U/L; no known drug allergies; she has limited income and relies on a neighbor for rides. What is the most appropriate intervention for this adherence barrier?
    Answer: Arrange home INR monitoring or coordinate local lab draws with results sent to the clinic, and synchronize follow-up by phone to adjust warfarin dosing as needed Overcoming barriers to effective medication therapy requires innovative monitoring solutions when transportation limits access to traditional healthcare settings. This patient's barrier is lack of transportation preventing INR monitoring for warfarin therapy, creating dangerous gaps in anticoagulation management with a recent supratherapeutic INR of 3.8. Arranging home INR monitoring or local lab draws with phone follow-up (Option A) is the BEST intervention because it maintains essential monitoring while eliminating transportation barriers through point-of-care or community-based testing. Option B (continuing without monitoring) risks life-threatening bleeding or thrombosis as warfarin requires regular INR assessment. Option C (switching to fish oil) dangerously abandons proven anticoagulation for an ineffective supplement. Option D (empirically increasing dose) is reckless given the recent elevated INR and lack of current monitoring. The clinical pearl is that transportation barriers to warfarin monitoring can be overcome through home INR devices, visiting nurse services, or community lab partnerships with remote result communication, ensuring safe anticoagulation management for patients with limited mobility.
13. A 64-year-old man (86 kg) with type 2 diabetes and chronic kidney disease stage 3a reports he has been rationing empagliflozin 10 mg daily (taking it every other day) because he cannot afford the $220 monthly cost after losing his job. Current medications: empagliflozin 10 mg daily (nonadherent due to cost), metformin 500 mg twice daily (adherent), glipizide 10 mg daily (adherent), losartan 100 mg daily (adherent). Labs: hemoglobin A1c 8.9$^2$), potassium 4.4 mEq/L, alanine aminotransferase 21 U/L; no known drug allergies; he has limited transportation but can receive mail. What is the most appropriate intervention for this adherence barrier?
    Answer: Enroll the patient in manufacturer assistance or copay support if eligible, assess formulary alternatives, and coordinate a lower-cost regimen with the prescriber while avoiding gaps in therapy Overcoming barriers to effective medication therapy requires comprehensive assessment of financial assistance options while maintaining continuous therapy for chronic conditions. This patient's barrier is the high cost of empagliflozin ($220/month) after job loss, leading to dangerous rationing of a cardio-renal protective medication. Enrolling in manufacturer assistance, assessing formulary alternatives, and coordinating a lower-cost regimen with the prescriber (Option A) is the BEST intervention because it systematically addresses affordability through multiple avenues while preventing treatment gaps. Option B (stopping all diabetes medications) dangerously abandons glycemic control with an A1c of 8.9%. Option C (doubling glipizide) risks hypoglycemia without monitoring and doesn't provide the cardio-renal benefits of SGLT2 inhibitors. Option D (every-other-day dosing) provides subtherapeutic drug levels and falsely suggests partial adherence is acceptable. The clinical pearl is that medication affordability barriers require proactive exploration of manufacturer programs, formulary alternatives, and therapeutic substitutions while maintaining continuous therapy, especially for medications with proven mortality benefits in diabetes and CKD.
14. A 45-year-old woman (63 kg) with moderate persistent asthma reports using fluticasone/salmeterol 250/50 mcg inhalation (1 inhalation twice daily) only when she feels short of breath because she believes it is a rescue inhaler; she uses albuterol metered-dose inhaler 2 puffs every 4 hours daily. Current medications: fluticasone/salmeterol 250/50 mcg 1 inhalation twice daily (misused), albuterol 90 mcg/puff 2 puffs every 4 hours as needed (overused), cetirizine 10 mg daily (adherent). Labs: none pertinent; serum creatinine 0.8 mg/dL; no known drug allergies. She has insurance and transportation but low health literacy and says, "I don't understand controller vs rescue." Which strategy best addresses this patient's health literacy issue?
    Answer: Use plain-language counseling to distinguish controller vs rescue, demonstrate inhaler technique, and have the patient teach back when to use each inhaler Overcoming barriers to effective medication therapy requires addressing fundamental misunderstandings about medication purpose and proper use. This patient's barrier is confusion between controller and rescue inhalers due to low health literacy, resulting in dangerous misuse—using the controller only for acute symptoms while overusing the rescue inhaler. Using plain-language counseling to distinguish controller versus rescue roles, demonstrating proper inhaler technique, and having the patient teach back when to use each (Option A) is the BEST intervention because it directly addresses the knowledge gap through interactive education and confirms understanding. Option B (stopping controller therapy) would worsen asthma control and contradicts evidence-based guidelines. Option C (adding oral prednisone) inappropriately introduces systemic corticosteroids without prescriber involvement and doesn't address the underlying confusion. Option D (providing package insert) fails because complex medical language in inserts exceeds the patient's health literacy level. The clinical pearl is that patients with low health literacy require interactive, plain-language education with teach-back confirmation to ensure they understand the fundamental difference between preventive and acute symptom medications.
15. A 61-year-old woman (74 kg) with hyperlipidemia and a prior myocardial infarction reports she stopped atorvastatin 80 mg nightly 2 months ago because she developed severe muscle pain and dark urine shortly after starting it; she is fearful of restarting any statin. Current medications: aspirin 81 mg daily (adherent), metoprolol succinate 50 mg daily (adherent), lisinopril 10 mg daily (adherent), atorvastatin 80 mg nightly (stopped due to adverse reaction). Labs: serum creatinine 1.1 mg/dL, alanine aminotransferase 28 U/L, aspartate aminotransferase 26 U/L; creatine kinase previously documented at 2,800 U/L during the episode; no known drug allergies otherwise. She has good insurance and transportation. What is the most appropriate intervention for this adverse drug reaction history?
    Answer: Recommend initiating ezetimibe 10 mg daily and communicate with the prescriber about statin-associated rhabdomyolysis history and need for alternative lipid-lowering therapy Overcoming barriers to effective medication therapy requires recognizing and appropriately managing severe adverse drug reactions while maintaining cardiovascular protection. This patient's barrier is fear of statins following documented rhabdomyolysis (CK 2,800 U/L with dark urine), preventing essential lipid-lowering therapy post-MI. Recommending ezetimibe and communicating with the prescriber about the rhabdomyolysis history (Option B) is the BEST intervention because it provides alternative lipid-lowering therapy while respecting the contraindication to statins and ensuring prescriber awareness. Option A (restarting high-dose statin) is dangerous and ignores the documented severe adverse reaction requiring discontinuation. Option C (red yeast rice) is inappropriate as it contains natural statins (monacolin K) that could trigger similar adverse effects and lacks standardization. Option D (every-other-week dosing) provides inadequate lipid control and still risks rhabdomyolysis recurrence. The clinical pearl is that documented statin-associated rhabdomyolysis requires permanent statin avoidance and alternative lipid-lowering strategies like ezetimibe, PCSK9 inhibitors, or bempedoic acid, with clear documentation and prescriber communication essential for patient safety.
16. A 73-year-old man (weight 72 kg) with hypertension and chronic kidney disease stage 3 is taking losartan 100 mg daily and was prescribed sodium zirconium cyclosilicate for recurrent hyperkalemia but has not started it because of cost. Labs: potassium 5.8 mEq/L, serum creatinine 1.9 mg/dL (estimated creatinine clearance 38 mL/min). Social history: fixed income, limited prescription coverage; transportation available. Allergies: none. What is the optimal alternative therapy given the patient's financial situation?
    Answer: Work with the prescriber to consider lower-cost potassium binder options if appropriate, review diet and contributing medications, and pursue coverage assistance for the prescribed binder Overcoming barriers to effective medication therapy includes optimizing management of hyperkalemia with affordable options in CKD. The key patient-specific barrier is the cost of sodium zirconium cyclosilicate, preventing use and risking persistent hyperkalemia. Working with prescriber for alternatives and assistance is the best choice as it reviews contributors, pursues coverage, and ensures safety. Stopping losartan risks hypertension, while increasing dietary potassium worsens hyperkalemia. Adding spironolactone exacerbates the issue. A clinical pearl is to assess diet and meds before binders in hyperkalemia. In practice, use a framework of evaluating costs, collaborating, and monitoring electrolytes.
17. A 62-year-old woman (weight 80 kg) with rheumatoid arthritis takes methotrexate 15 mg once weekly but has been taking it daily for the last 5 days because the label said "take 6 tablets weekly" and she misunderstood. Current medications: methotrexate 2.5 mg tablets (intended 6 tablets once weekly), folic acid 1 mg daily, ibuprofen 400 mg as needed. Labs today: alanine aminotransferase 78 units/L, aspartate aminotransferase 70 units/L, serum creatinine 1.1 mg/dL. Social history: limited health literacy; no language barrier; transportation available. Allergies: none. Which strategy best addresses this patient's health literacy issue?
    Answer: Immediately counsel to stop methotrexate and contact the prescriber/poison control as appropriate for potential toxicity, then implement clear weekly-only labeling, dosing calendar, and teach-back before restarting per prescriber Overcoming barriers to effective medication therapy necessitates immediate correction of dosing errors in high-risk medications like methotrexate. The key patient-specific barrier is misunderstanding weekly dosing due to low literacy, leading to daily intake and potential toxicity. Counseling to stop, contact prescriber, and implement tools is the best choice as it prevents harm, clarifies with aids, and ensures safe restart. Continuing daily risks severe toxicity, while switching to leflunomide bypasses oversight. Providing the guide alone doesn't confirm understanding. A clinical pearl is to use explicit labeling for weekly meds. In practice, use a framework of verifying errors, intervening urgently, and educating with tools.
18. A 41-year-old woman (weight 66 kg) with hypothyroidism is taking levothyroxine 100 mcg daily but often takes it with breakfast and her calcium supplement because she is rushing to work. She reports persistent fatigue. Current medications: levothyroxine 100 mcg daily (inconsistent timing), calcium carbonate 500 mg twice daily, multivitamin daily. Labs: thyroid-stimulating hormone 9.8 mIU/L, serum creatinine 0.8 mg/dL. Social history: adequate finances; busy schedule; moderate health literacy. Allergies: none. What is the most appropriate intervention for this adherence barrier?
    Answer: Counsel to take levothyroxine on an empty stomach separated from calcium/multivitamins by at least 4 hours, and help the patient choose a consistent routine that fits her schedule Overcoming barriers to effective medication therapy involves optimizing administration timing to maximize absorption and efficacy. The key patient-specific barrier is inconsistent levothyroxine timing with food/supplements, reducing absorption and causing elevated TSH. Counseling on empty stomach separation and routine is the best choice as it corrects technique, fits her schedule, and improves outcomes. Taking with calcium worsens absorption, while doubling dose risks hyperthyroidism. Stopping for iodine lacks evidence. A transferable pearl is to separate levothyroxine from interferers by 4 hours. In practice, employ a framework of verifying routines, educating on interactions, and monitoring labs.
19. A patient misses daytime visits due to work and transit. Which option best addresses both barriers?
    Answer: Offer evening virtual visits Evening visits remove the daytime work conflict, and virtual visits remove the need to travel, so they address both barriers at once. A transit route map is tempting because it tackles getting to the clinic, but it does nothing about missing work during daytime hours.
20. A 67-year-old man (weight 84 kg) with coronary artery disease status post stent, type 2 diabetes mellitus, and gastroesophageal reflux disease reports he stopped clopidogrel 75 mg daily 2 weeks ago because it caused "severe hives" shortly after starting it last year; he never told his cardiologist. Current medications: aspirin 81 mg daily, metformin 500 mg twice daily, omeprazole 20 mg daily, and nitroglycerin 0.4 mg sublingual as needed. Labs: serum creatinine 1.0 mg/dL, alanine aminotransferase 30 units/L, hemoglobin A1c 7.8%. Social history: good transportation and insurance. Allergies/adverse reactions: clopidogrel—urticaria. What is the most appropriate intervention for this adherence barrier?
    Answer: Document the clopidogrel reaction, assess severity/timing, and contact the cardiology team to discuss an alternative antiplatelet agent and allergy evaluation Overcoming barriers to effective medication therapy involves properly managing reported adverse reactions to prevent unnecessary discontinuation while ensuring patient safety. The key patient-specific barrier is the unreported clopidogrel-induced hives, leading to self-discontinuation and increased cardiovascular risk post-stent. Documenting the reaction and contacting cardiology for alternatives is the best choice as it facilitates a thorough assessment, potential allergy evaluation, and safe antiplatelet substitution. Restarting clopidogrel with diphenhydramine is suboptimal without severity assessment, risking recurrence, while advising to stop aspirin ignores its necessity and misattributes the allergy. Taking clopidogrel only symptomatically reduces efficacy and fails to address the barrier systematically. A transferable pearl is to always verify allergy details like timing and severity before recommending changes. In practice, employ a framework of documenting reactions, collaborating with specialists, and educating patients on reporting to mitigate similar adherence issues.

Start this quiz